Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

LGVN vs IQV vs CRL vs ICLR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
LGVN
Longeveron Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$20M
5Y Perf.-98.9%
IQV
IQVIA Holdings Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$30.32B
5Y Perf.-7.3%
CRL
Charles River Laboratories International, Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$8.98B
5Y Perf.-37.9%
ICLR
ICON Public Limited Company

Medical - Diagnostics & Research

HealthcareNASDAQ • IE
Market Cap$9.54B
5Y Perf.-31.1%

LGVN vs IQV vs CRL vs ICLR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
LGVN logoLGVN
IQV logoIQV
CRL logoCRL
ICLR logoICLR
IndustryBiotechnologyMedical - Diagnostics & ResearchMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$20M$30.32B$8.98B$9.54B
Revenue (TTM)$1M$16.63B$4.03B$8.10B
Net Income (TTM)$-23M$1.39B$-185M$599M
Gross Margin43.7%26.1%24.9%26.9%
Operating Margin-19.4%13.9%11.8%12.2%
Forward P/E14.1x16.0x10.7x
Total Debt$824K$16.17B$3.07B$3.60B
Cash & Equiv.$5M$1.98B$214M$539M

LGVN vs IQV vs CRL vs ICLRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

LGVN
IQV
CRL
ICLR
StockFeb 21May 26Return
Longeveron Inc. (LGVN)1001.1-98.9%
IQVIA Holdings Inc. (IQV)10092.7-7.3%
Charles River Labor… (CRL)10062.1-37.9%
ICON Public Limited… (ICLR)10068.9-31.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: LGVN vs IQV vs CRL vs ICLR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: IQV leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Longeveron Inc. is the stronger pick specifically for capital preservation and lower volatility. CRL and ICLR also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
LGVN
Longeveron Inc.
The Defensive Pick

LGVN is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 0.95, Low D/E 14.5%, current ratio 1.33x
  • Beta 0.95, current ratio 1.33x
  • Beta 0.95 vs ICLR's 1.60, lower leverage
Best for: sleep-well-at-night and defensive
IQV
IQVIA Holdings Inc.
The Income Pick

IQV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 2 yrs, beta 1.33
  • Rev growth 5.9%, EPS growth 4.7%, 3Y rev CAGR 4.2%
  • 166.5% 10Y total return vs CRL's 119.2%
  • PEG 0.35 vs ICLR's 1.53
Best for: income & stability and growth exposure
CRL
Charles River Laboratories International, Inc.
The Momentum Pick

CRL is the clearest fit if your priority is momentum.

  • +32.8% vs LGVN's -42.8%
Best for: momentum
ICLR
ICON Public Limited Company
The Value Play

ICLR is the clearest fit if your priority is value.

  • Lower P/E (10.7x vs 16.0x)
Best for: value
See the full category breakdown
CategoryWinnerWhy
GrowthIQV logoIQV5.9% revenue growth vs LGVN's -49.9%
ValueICLR logoICLRLower P/E (10.7x vs 16.0x)
Quality / MarginsIQV logoIQV8.3% margin vs LGVN's -18.9%
Stability / SafetyLGVN logoLGVNBeta 0.95 vs ICLR's 1.60, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)CRL logoCRL+32.8% vs LGVN's -42.8%
Efficiency (ROA)IQV logoIQV4.7% ROA vs LGVN's -143.2%, ROIC 8.7% vs -5.9%

LGVN vs IQV vs CRL vs ICLR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

LGVNLongeveron Inc.

Segment breakdown not available.

IQVIQVIA Holdings Inc.
FY 2025
Research And Development Solutions
54.5%$8.9B
Technology And Analytics Solutions
40.6%$6.6B
Contract Sales And Medical Solutions
4.8%$788M
CRLCharles River Laboratories International, Inc.
FY 2025
Discovery and Safety Assessment
59.8%$2.4B
Research Models and Services
21.1%$846M
Manufacturing Support
19.1%$766M
ICLRICON Public Limited Company
FY 2012
Clinical Research
92.2%$1.0B
Central Laboratory
7.8%$87M

LGVN vs IQV vs CRL vs ICLR — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLIQVLAGGINGLGVN

Income & Cash Flow (Last 12 Months)

IQV leads this category, winning 5 of 6 comparable metrics.

IQV is the larger business by revenue, generating $16.6B annually — 13871.6x LGVN's $1M. IQV is the more profitable business, keeping 8.3% of every revenue dollar as net income compared to LGVN's -18.9%. On growth, IQV holds the edge at +8.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricLGVN logoLGVNLongeveron Inc.IQV logoIQVIQVIA Holdings In…CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
RevenueTrailing 12 months$1M$16.6B$4.0B$8.1B
EBITDAEarnings before interest/tax-$22M$3.5B$757M$1.4B
Net IncomeAfter-tax profit-$23M$1.4B-$185M$599M
Free Cash FlowCash after capex-$19M$2.7B$391M$996M
Gross MarginGross profit ÷ Revenue+43.7%+26.1%+24.9%+26.9%
Operating MarginEBIT ÷ Revenue-19.4%+13.9%+11.8%+12.2%
Net MarginNet income ÷ Revenue-18.9%+8.3%-4.6%+7.4%
FCF MarginFCF ÷ Revenue-15.9%+16.1%+9.7%+12.3%
Rev. Growth (YoY)Latest quarter vs prior year-39.5%+8.4%+1.2%+0.6%
EPS Growth (YoY)Latest quarter vs prior year+11.1%+15.0%-160.0%-98.7%
IQV leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

ICLR leads this category, winning 5 of 7 comparable metrics.

At 13.1x trailing earnings, ICLR trades at a 42% valuation discount to IQV's 22.8x P/E. Adjusting for growth (PEG ratio), IQV offers better value at 0.56x vs ICLR's 1.87x — a lower PEG means you pay less per unit of expected earnings growth.

MetricLGVN logoLGVNLongeveron Inc.IQV logoIQVIQVIA Holdings In…CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
Market CapShares × price$20M$30.3B$9.0B$9.5B
Enterprise ValueMkt cap + debt − cash$16M$44.5B$11.8B$12.6B
Trailing P/EPrice ÷ TTM EPS-0.66x22.79x-62.52x13.12x
Forward P/EPrice ÷ next-FY EPS est.14.06x16.00x10.73x
PEG RatioP/E ÷ EPS growth rate0.56x1.87x
EV / EBITDAEnterprise value multiple12.97x12.98x7.95x
Price / SalesMarket cap ÷ Revenue16.56x1.86x2.24x1.15x
Price / BookPrice ÷ Book value/share2.64x4.67x2.81x1.09x
Price / FCFMarket cap ÷ FCF14.78x17.31x8.53x
ICLR leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

IQV leads this category, winning 4 of 9 comparable metrics.

IQV delivers a 22.1% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-200 for LGVN. LGVN carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), ICLR scores 7/9 vs LGVN's 2/9, reflecting strong financial health.

MetricLGVN logoLGVNLongeveron Inc.IQV logoIQVIQVIA Holdings In…CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
ROE (TTM)Return on equity-199.8%+22.1%-5.7%+6.3%
ROA (TTM)Return on assets-143.2%+4.7%-2.5%+3.6%
ROICReturn on invested capital-5.9%+8.7%+6.3%+6.5%
ROCEReturn on capital employed-159.8%+11.0%+8.1%+7.8%
Piotroski ScoreFundamental quality 0–92447
Debt / EquityFinancial leverage0.15x2.44x0.95x0.38x
Net DebtTotal debt minus cash-$4M$14.2B$2.9B$3.1B
Cash & Equiv.Liquid assets$5M$2.0B$214M$539M
Total DebtShort + long-term debt$824,000$16.2B$3.1B$3.6B
Interest CoverageEBIT ÷ Interest expense3.10x6.38x3.96x
IQV leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CRL leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in IQV five years ago would be worth $7,621 today (with dividends reinvested), compared to $152 for LGVN. Over the past 12 months, CRL leads with a +32.8% total return vs LGVN's -42.8%. The 3-year compound annual growth rate (CAGR) favors CRL at -1.4% vs LGVN's -70.0% — a key indicator of consistent wealth creation.

MetricLGVN logoLGVNLongeveron Inc.IQV logoIQVIQVIA Holdings In…CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
YTD ReturnYear-to-date+43.6%-20.7%-10.1%-33.7%
1-Year ReturnPast 12 months-42.8%+16.5%+32.8%-10.0%
3-Year ReturnCumulative with dividends-97.3%-5.9%-4.2%-34.1%
5-Year ReturnCumulative with dividends-98.5%-23.8%-46.9%-45.4%
10-Year ReturnCumulative with dividends-98.9%+166.5%+119.2%+91.0%
CAGR (3Y)Annualised 3-year return-70.0%-2.0%-1.4%-13.0%
CRL leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LGVN and CRL each lead in 1 of 2 comparable metrics.

LGVN is the less volatile stock with a 0.95 beta — it tends to amplify market swings less than ICLR's 1.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRL currently trades 79.5% from its 52-week high vs LGVN's 47.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricLGVN logoLGVNLongeveron Inc.IQV logoIQVIQVIA Holdings In…CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
Beta (5Y)Sensitivity to S&P 5000.93x1.32x1.44x1.64x
52-Week HighHighest price in past year$1.80$247.05$228.88$211.00
52-Week LowLowest price in past year$0.47$134.65$131.30$66.57
% of 52W HighCurrent price vs 52-week peak+47.3%+72.3%+79.5%+59.2%
RSI (14)Momentum oscillator 0–10041.158.557.262.1
Avg Volume (50D)Average daily shares traded6.7M1.6M806K1.1M
Evenly matched — LGVN and CRL each lead in 1 of 2 comparable metrics.

Analyst Outlook

IQV leads this category, winning 1 of 1 comparable metric.

Analyst consensus: IQV as "Buy", CRL as "Buy", ICLR as "Buy". Consensus price targets imply 26.3% upside for IQV (target: $226) vs 13.5% for CRL (target: $206).

MetricLGVN logoLGVNLongeveron Inc.IQV logoIQVIQVIA Holdings In…CRL logoCRLCharles River Lab…ICLR logoICLRICON Public Limit…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$225.63$206.43$152.13
# AnalystsCovering analysts443630
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises121
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+4.1%+4.0%+5.2%
IQV leads this category, winning 1 of 1 comparable metric.
Key Takeaway

IQV leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ICLR leads in 1 (Valuation Metrics). 1 tied.

Best OverallIQVIA Holdings Inc. (IQV)Leads 3 of 6 categories
Loading custom metrics...

LGVN vs IQV vs CRL vs ICLR: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is LGVN or IQV or CRL or ICLR a better buy right now?

For growth investors, IQVIA Holdings Inc.

(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -49. 9% for Longeveron Inc. (LGVN). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 7x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — LGVN or IQV or CRL or ICLR?

On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.

1x versus IQVIA Holdings Inc. at 22. 8x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus ICON Public Limited Company's 1. 53x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — LGVN or IQV or CRL or ICLR?

Over the past 5 years, IQVIA Holdings Inc.

(IQV) delivered a total return of -23. 8%, compared to -98. 5% for Longeveron Inc. (LGVN). Over 10 years, the gap is even starker: IQV returned +166. 6% versus LGVN's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — LGVN or IQV or CRL or ICLR?

By beta (market sensitivity over 5 years), Longeveron Inc.

(LGVN) is the lower-risk stock at 0. 93β versus ICON Public Limited Company's 1. 64β — meaning ICLR is approximately 76% more volatile than LGVN relative to the S&P 500. On balance sheet safety, Longeveron Inc. (LGVN) carries a lower debt/equity ratio of 15% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — LGVN or IQV or CRL or ICLR?

By revenue growth (latest reported year), IQVIA Holdings Inc.

(IQV) is pulling ahead at 5. 9% versus -49. 9% for Longeveron Inc. (LGVN). On earnings-per-share growth, the picture is similar: ICON Public Limited Company grew EPS 28. 8% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, ICLR leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — LGVN or IQV or CRL or ICLR?

ICON Public Limited Company (ICLR) is the more profitable company, earning 9.

6% net margin versus -1893. 6% for Longeveron Inc. — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -1942. 2% for LGVN. At the gross margin level — before operating expenses — LGVN leads at 67. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is LGVN or IQV or CRL or ICLR more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus ICON Public Limited Company's 1. 53x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10. 7x forward P/E versus 16. 0x for Charles River Laboratories International, Inc. — 5. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 26. 3% to $225. 63.

08

Which pays a better dividend — LGVN or IQV or CRL or ICLR?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is LGVN or IQV or CRL or ICLR better for a retirement portfolio?

For long-horizon retirement investors, Longeveron Inc.

(LGVN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 93)). ICON Public Limited Company (ICLR) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LGVN: -98. 9%, ICLR: +90. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between LGVN and IQV and CRL and ICLR?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LGVN is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock; CRL is a small-cap quality compounder stock; ICLR is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

LGVN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 26%
Run This Screen
Stocks Like

IQV

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

CRL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 14%
Run This Screen
Stocks Like

ICLR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform LGVN and IQV and CRL and ICLR on the metrics below

Revenue Growth>
%
(LGVN: -39.5% · IQV: 8.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.